University of Ottawa

Researchers identified new drug targets for retinitis pigmentosa and other inherited retinal diseases, revealing shared critical pathways in disease models, published in Molecular & Cellular Proteomics.

CHEST 2024 highlighted advancements in pulmonary disease, PE, and pulmonary hypertension, focusing on personalized care, clinical trials, and new COPD treatments. Discussions included sleep medicine, racial disparities in pulmonary care, and tailored learning opportunities.

Recent FDA approvals and accelerated pathways have led to multiple therapies for Duchenne muscular dystrophy (DMD), with more in development. Despite progress, DMD remains a heterogeneous disease with over 2,000 mutations, necessitating new treatments. Satellos, a Canadian biotech, is developing a dystrophin-independent, small molecule approach to treat DMD, potentially beneficial regardless of mutation type.

Shawn Aaron, MD (University of Ottawa) presents 'Early Diagnosis and Treatment of Asthma and COPD' on Oct 11, 2024, 1-2 p.m. ET. Join via Zoom: https://duke.zoom.us/j/98571026630?pwd=COEg4a7tagfZe59V0yFjgK88fdMZiV.1, Passcode: 654855.